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CARDIOVASCULAR MEDICINE
Evolution of statin prescribing 1994–2001: a case of
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Objective: To study trends in the use of lipid lowering drugs in the UK, and to assess which patient fac-
tors influence prescribing.
Methods: Routinely collected computerised medical data were analysed from 142 general practices
across England and Wales that provide data for the Doctors’ Independent Network database. Subjects
included were people aged 35 years or more with treated ischaemic heart disease, averaging annu-
ally over 30 000. The temporal trend from 1994 to 2001 in prescription of lipid lowering drugs and
daily statin dose and the odds ratios (ORs) for receiving a statin prescription in 1998 were examined.
Results: Lipid lowering drug prescribing increased greatly over time, entirely because of statins, so that
in 2001 56.3% of men and 41.1% of women with ischaemic heart disease received lipid lowering
drugs. However, 33% of these patients were on a < 20 mg simvastatin daily equivalent. In 1998 the
OR for receiving a statin fell from 1 at age 55–64 to 0.64 at 65–74 and 0.16 at 75–84 years. The
age effect was similar in those without major comorbidity. Revascularised patients were much more
likely to receive a statin than those with angina (OR 3.92, 95% confidence interval (CI) 3.57 to 4.31).
Men were more likely to receive a statin than women (OR 1.62, 95% CI 1.54 to 1.71) but this differ-
ence disappeared after adjustment for age and severity of disease (OR 1.06). Geographical region
had little effect but there was a very weak socioeconomic gradient.
Conclusions: Although prescribing has increased, many patients who may benefit from lipid lowering
drugs either do not receive it or are undertreated, possibly because of lack of awareness of the relative
potency of the different statins. Patients with angina and the elderly are less likely to receive treatment
that may prevent a coronary event.
The effectiveness of the hydroxymethyl glutaryl coenzymeA reductase inhibitors (statins) in secondary preventionof ischaemic heart disease (IHD) is well established.1 2
Such secondary prevention is a public health priority.3 Statins
have become by far the most widely prescribed lipid lowering
drugs4 and yet there is evidence that many patients who may
benefit from them are not receiving these drugs. In 1998 fewer
than a third of patients with IHD in England were receiving
lipid lowering drugs.5 Another recent study reported that use
of lipid lowering drugs in patients with IHD remained low and
that even among patients receiving them, fewer than half had
a total cholesterol concentration below 5.0 mmol/l.6 It has
been suggested that sex strongly influences lipid lowering
drug prescribing and other secondary prevention measures,7
with 31% of men but only 21% of women in the survey being
prescribed such drugs. However, a recent study found older
age to be the most important association with lower statin
use.8
We used the Doctors’ Independent Network (DIN) database
to determine trends in statin prescribing, including dosage,
over time and to examine to what degree patient factors and
practice affect any inequalities in the prescription of these
drugs.
METHODS
The DIN database
The DIN database contains routinely collected anonymised
patient records from general practitioners using Torex System
5 practice software. It has been used for epidemiological
research9 but to date its main use has been for pharmaceutical
market research. About 300 practices and 1400 general practi-
tioners have contributed data, of which we have selected 142
practices on a series of quality indicators including complete-
ness of data recording, linkage of records to prescriptions
issued, and duration of data provision. We have processed the
registers in these practices to remove patients who remain
registered with the practice after they have left the practice or
died and to ensure that the distribution of age groups within
these practices corresponds well with nationally available data
and with the age distribution of patients within the General
Practice Research Database (GPRD). Over one million patient
years of information are available in DIN annually.
General practitioners in DIN are encouraged to enter all
surgery contacts with patients onto their clinical system.
Diagnoses, procedures, and investigations are recorded using
four-character Read codes, as are all prescriptions. A unique
aspect of DIN is that it contains an indicator of social circum-
stance allocated to patients at the post code level. This is the
ACORN index (a classification of residential neighbourhoods),
a commercially available geodemographic segmentation
system.10 It provides many levels of detail but at its most
aggregated level categorises residential neighbourhoods into
six groups along a dimension from “thriving” to “striving”.
ACORN has been used in research as an indicator of
deprivation.11 12 In DIN, the ACORN score is attached to records
by the practice computer before anonymisation and data
extraction. For technical reasons not all practices or patients in
DIN have an ACORN score assigned.
Patient selection
For the years 1994 to 2001 we selected patients aged 35 years
or more who were registered with practices on 31 December of
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that year and who had been registered for at least six months
before this date. In doing this we followed the methods used
by the compilers of key health statistics (KHS).13 We similarly
used the KHS definition of “treated IHD”, this being the pres-
ence of a coded entry for IHD anywhere in the records before
31 December plus a prescription for any cardiovascular system
drug (British National Formulary, chapter 2) or aspirin in the
year of interest.
For these IHD patients, we extracted data on age, sex, regis-
tered practice, National Health Service region, smoking status,
ACORN score (if present), type of IHD, time from diagnosis,
and prescription information. Type of IHD was divided into
non-specific IHD Read codes, angina, any myocardial infarc-
tion (MI), and revascularisation (any coronary artery revascu-
larisation procedure). Each patient could have only one IHD
type, and the most clinically significant diagnosis in each
record was chosen, revascularisation being most and non-
specific IHD being least significant. For patients who had been
prescribed statins, we extracted the type of statin, strength,
and dose frequency and used this information to calculate the
daily dose in milligrams. From this we derived an approximate
equivalent daily dose of simvastatin. This takes into account
the different potencies per milligram of the various statins and
presents them as an equivalent dose of the most widely used
statin.14
To investigate whether any age trends were attributable to
increasing levels of comorbidity and prescribing we repeated
our analyses of 1998 data restricted to patients with IHD but
without a diagnosis of stroke, cancer,mental disorder, or heart
failure. We further restricted our analyses to those not receiv-
ing a prescription for any other British National Formulary
chapter.
Analysis
We examined prevalence of recorded IHD, percentage of IHD
patients receiving lipid lowering drugs, and daily dose of stat-
ins (where prescribed) annually from 1994 to 2001. For the
principal analysis the main outcome variable was prescription
of lipid lowering drugs in 1998. This was the year the most
recent KHS were published,13 although results were similar for
more recent years. Odds ratios (ORs) were derived from logis-
tic regressions to determine the influence of the predictor
variables on this outcome. Analyses of variation between the
142 practices in prescribing rates in 1998 were based on
analyses of variance with practice as the unit of analysis.
We wished to validate both IHD rates and the proportion of
patients with IHD who were prescribed statins against KHS
data from the GPRD. Because there are clear regional
variations in IHD rates and because of differences in the
regional distribution of the two databases (60% of DIN
practices are in the south of England compared with 42% of
GPRD practices), we used direct standardisation to the GPRD
regional structure to derive DIN prevalence rates for treated
IHD for comparison with KHS rates.
RESULTS
Prevalence of IHD and lipid lowering drug prescription
Prevalence of treated IHD rose from 6.4% to 7.7% between
1994 and 2001, reflecting both the aging of the population and
increasing levels of treatment. Much more pronounced was
the rise in lipid lowering drug prescribing among patients
with IHD (fig 1 and table w1). The increase in prescribing,
nearly all accounted for by prescriptions for statins, is striking,
but in 2001 only 56.3% of men and 41.1% of women with IHD
received a prescription for lipid lowering drugs. Secular trends
in statin prescribing rose steadily in all age groups and sepa-
rately for those with angina, MI, and those undergoing
surgery (table w2), though differentials by age and type of
IHD are apparent in all years. The number of patients not cur-
rently on any lipid lowering drugs but with a prescription for
a statin in a previous year was low (fig 1).
Statin dose
Figure 2 shows the trend in daily dose, adjusted to milligram
equivalence with simvastatin, among those prescribed a
statin. If a 20 mg daily dose of simvastatin is taken as the
amount required to achieve a mean reduction of 25% in total
cholesterol1 14 then in 1994 only 22.6% of men and 21.9% of
women were given a statin dose likely to achieve this
reduction. By 2001 this had risen to 67.6% of men and 67.4%
of women. Of those taking a 2.5–5 mg/day equivalent dose
(8.1% of men and 7.4% of women in 2001) most were taking
lower doses of the less potent statins, pravastatin and fluvas-
tatin (and cerivastatin, now withdrawn in the UK).
Figure 1 Trends in statin prescription in patients with ischaemic
heart disease (IHD) by sex. LLT, lipid lowering treatment.
Figure 2 Trends in statin doses (equivalent daily doses of
simvastatin). Simvastatin 20 mg is required to achieve a mean
reduction of 25% in total cholesterol.
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Factors influencing statin use in 1998
Age had the strongest association with statin prescription,
with 44.9% of patients aged 35–64 years receiving a statin
compared with just 10.4% of those aged 75–84 and only 1.2%
of those aged over 85. Further analysis was restricted to ages
35–85 (table 1). Type of IHD was also strongly related:
revascularised patients had an OR of 3.92 for receiving a sta-
tin compared with patients with angina, after adjustment for
other factors.
Statin use decreased in a graded fashion with time from
diagnosis, from 39.6% for those with a diagnosis in the previ-
ous year to 20.3% of those given a diagnosis more than five
years previously (OR 2.19 after adjustment). Smokers were
slightly less likely to receive statins. There was a weak but sig-
nificant trend of decreasing statin treatment with increasing
ACORN score. Thus, patients in “striving” areas were less
likely to receive a statin than in “thriving” areas. Although
there was significant regional heterogeneity, there was no evi-
dence of any north–south trend or other geographical
patterning.
Men were more likely to receive a statin than women (OR
1.62); however, adjustment for confounding variables effec-
tively removed this difference (OR 1.06). This was because
women with IHD were older, more likely to have an angina
diagnosis than men (63.1% v 42.1%), and less likely to have
been revascularised (3.8% v 12.5%). Further analyses showed
that while among patients with angina, men were more likely
to receive statins than women even after adjustment (OR 1.33,
95% confidence interval 1.18 to 1.49), among revascularised
patients men were less likely than women to receive a statin
after adjustment for other factors (OR 0.60, 95% confidence
interval 0.48 to 0.76).
There was a wide variation in prescribing patterns between
practices (fig 3) that lessened only slightly when age adjusted
rates were used instead (data not shown). In 1998, the
prescribing rates among those aged 35–85 ranged from
12–51% (interquartile range 25–33%), but in 2000 it was
23–69% (interquartile range 40–52%). In 1998 statin prescrib-
ing rates were unrelated to practice size (p = 0.63), being 29%
in the 12 practices with under 3000 and 27% in the 8 practices
with over 12 000 patients. Nor was statin prescribing
associated with degree of urbanisation (9 inner city practices
average 28%, 107 urban practices 27%, and 26 rural practices
27%; p = 0.79)
To investigate the age trend further we examined statin
prescribing among patients with IHD but without any
diagnosis of stroke,mental disorder, cancer, or heart failure. At
all ages the percentage of these “healthy” patients prescribed
statins was only slightly higher than for all patients and the
same age gradient was apparent, ranging from 45% (90 of
Table 1 Factors influencing statin usage among IHD diagnosed patients aged 35–84 in 1998 (n = 30 448)
Variable Number r % OR 95% CI Adjusted OR 95% CI*
Age range (years)
35–44 395 164 41.5 0.91 0.74to1.11 0.90 0.73to1.12
45–54 2418 1170 48.4 1.20 1.09to1.32 1.18 1.07to1.30
55–64 6387 2798 43.8 1 1
65–74 11334 3734 33.0 0.63 0.59to0.67 0.64 0.60to0.69
75–84 9901 1030 10.4 0.15 0.14to0.16 0.16 0.15to0.18
Sex
Female 12495 2936 23.5 1 1
Male 17940 5960 33.2 1.62 1.54to1.71 1.06 1.00to1.13
Regional Health Authority
Anglia & Oxford (21)† 4275 1280 29.9 1.01 0.93to1.10 0.94 0.86to1.03
North Thames (15) 2570 753 29.3 0.98 0.89to1.08 0.98 0.88to1.10
North West (8) 2101 652 31.0 1.06 0.95to1.18 1.00 0.89to1.13
North & Yorkshire (20) 5807 1512 26.0 0.83 0.77to0.90 0.82 0.75to0.89
Scotland (1) 62 31 50.0 2.36 1.43to3.90 2.60 1.49to4.53
South Thames (16) 2790 985 35.3 1.29 1.17to1.42 1.32 1.19to1.46
South & West (31) 6423 1910 29.7 1 1
Trent (16) 3903 1102 28.2 0.93 0.85to1.02 0.93 0.84to1.02
Wales (4) 1059 269 25.4 0.81 0.69to0.93 0.86 0.73to1.02
West Midlands (10) 1445 402 27.8 0.91 0.80to1.03 0.89 0.77to1.02
Type
Non-specific IHD 3174 760 23.9 1.13 1.04to1.24 1.12 1.01to1.24
Angina 15445 3359 21.8 1 1
Myocardial infarction 9094 3248 35.7 2.00 1.89to2.12 1.96 1.84to2.09
Revascularisation 2722 1529 56.2 4.61 4.24to5.02 3.92 3.57to4.31
Time since diagnosis
0–1 years 6273 2484 39.6 2.58 2.41to2.76 2.19 2.02to2.37
1–3 years 7594 2649 34.9 2.11 1.97to2.25 1.92 1.79to2.07
3–5 years 5438 1505 27.7 1.50 1.40to1.62 1.31 1.20to1.42
>5 years 11130 2258 20.3 1 1
ACORN
Thriving 6468 2080 32.2 1 1
Expanding 2202 733 33.3 1.05 0.95to1.17 0.95 0.84to1.08
Rising 926 232 25.1 0.71 0.60to0.83 0.84 0.69to1.03
Settling 5684 1624 28.6 0.84 0.78to0.91 0.93 0.84to1.02
Aspiring 3240 852 26.3 0.75 0.69to0.83 0.81 0.72to0.91
Striving 3881 1078 27.8 0.81 0.74to0.89 0.75 0.66to0.84
No ACORN score 8034 2297 28.6 0.85 0.79to0.91 0.98 0.83to1.15
Smoking status
Never 10871 3014 27.7 1 1
Former 11075 3569 32.2 1.25 1.18to1.32 1.06 0.99to1.14
Current 5124 1680 32.8 1.26 1.17to1.36 0.90 0.83to0.98
Not recorded 3365 633 18.8 0.60 0.55to0.67 0.72 0.64to0.80
*Adjusted for all other variables in table and practice (except region, which is not adjusted for practice).
†The number of practices in each region is shown in parentheses.
ACORN, a classification of residential neighbourhoods; CI, confidence interval; IHD, ischaemic heart disease; OR, odds ratio.
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202) at age 35–44, through 54% (611 of 1139) at age 45–54,
45% (1307 of 2870) at age 55–64, 34% (1680 of 4949) at age
65–74, 12% (402 of 3427) at age 75–84, and 2% (14 of 880)
over age 85 years. Further restriction based on numbers of
drugs prescribed also made little difference to the trend (data
not presented).
Analyses of factors influencing prescribing in 2000 and
2001 provided very similar findings to those for 1998 but with
wider confidence intervals (data not presented). In particular,
there was no evidence that the age differences were diminish-
ing with prescribing rates in 2001, being 66.5% (175 of 263) at
35–44, through 68.1% (988 of 1450) at age 45–54, 68.4% (2823
of 4130) at 55–64, 61.0% (4314 of 7075) at 65–74, 33.8% (2294
to 6797) at 75–84, and 5.3% (125 of 2382) over 85 years.
Validation of DIN against GPRD in 1998
Region adjusted prevalence rates of treated IHD in DIN were
7.29% for men and 5.37% for women, compared with GPRD
published rates of 7.27% for men and 5.42 for women.13
In 1998 the percentage of patients aged> 35 with IHD pre-
scribed statins in DIN (31.4% of men and 20.0% of women)
was very similar to the figures that can be derived from GPRD
data (29% of men and 19% of women).13
DISCUSSION
IHD rates obtained from DIN are very similar to GPRD
published rates, as are statin prescription rates, providing
external validation of the trends in IHD and statin prevalence
obtained from DIN. No data from GPRD have been published
since 1998.
Lipid lowering drug prescription for patients with IHD has
grown greatly since 1994 and continues to increase. Statins
account for almost all of this growth. Despite this, many
patients who may benefit from this treatment still do not
receive it.
The trend in statin daily doses had been towards the higher
doses more likely to produce the 20–25% reductions in total
cholesterol concentration suggested by guidelines3 but many
patients remain on lower doses. Many such patients were on
low to medium doses of the less potent statins and probably
would have benefited from a higher dose or a change to a more
potent statin. These data fit with the recent study by Whincup
and colleagues.6
Examining the secular trends in our data (table w1) it is
apparent that the increase in prescribing of statins for second-
ary prevention of IHD has been steady with no obvious impact
of the national guidelines issued in 199715 and 1998.16
Moreover, the secular increase is similar in all age groups and
separately for those with angina, those with MI, and those
undergoing surgery (table w2), though differentials by age
and type of IHD are apparent in all years.
In implementation of any new guidance it is inevitable that
some practices lead, while others lag behind. However, some
years after dissemination of evidence regarding the effective-
ness of statins, there remains wide variation between general
practices in their prescription of statins for IHD. Only limited
exploration of practice variation was possible with no evidence
that either practice size or degree of urbanisation was related.
In fact, practice variation is pronounced for almost any process
measure in primary care. Attempts to explain this variation
have met with only limited success. Thus, a study of practice
variation in prescribing costs found that easily recorded prac-
tice factors such as age and sex of general practitioners and
other practice characteristics such as computerisation and
staff structure explained little.17 It seems likely that to under-
stand practice (and individual doctor) variation a qualitatively
different type of study that will collect data on attitudes and
responses of individual doctors will be necessary.18 At the same
time, where targets have been introduced into primary care
with clear incentives for reaching them, practice variation has
greatly reduced. Such an example is cervical cytology screen-
ing. It is too early to assess the impact of the National Service
Framework for coronary heart disease (CHD) on reducing
practice variation in statin prescribing.
An important strength of the present study is that practice
differences were controlled for when assessing the role of
other factors in statin prescribing. Of the other factors that
may influence the decision to prescribe a statin, the type of
IHD and the age of the patient appear to be most important. It
may be that doctors regard IHD in younger people as more
serious than in older people. However, since 1999 there has
been clear trial evidence that patients aged 65–74 benefit as
much as younger patients in relative terms, while the absolute
risk reduction is probably greater.19 The logical presumption
was that similar benefits would be seen at older ages. This has
recently been confirmed by the MRC/BHF heart protection
study,20 which has shown clear benefit in those aged 70–80
years at randomisation. Unfortunately, “agist” patient selec-
tion in the earlier published trials is reinforced by the National
Service Framework for CHD, which does not specifically men-
tion the need for statin treatment over age 75,3 and the
National Service Framework for older people, which simply
refers one to the framework for CHD.21
It may also be that doctors perceive coronary artery proce-
dures as being more significant than angina. However, the
higher statin prescribing rate among patients with MI and
coronary artery bypass graft more probably reflects treatment
being initiated in a secondary care setting. As the purpose of
lipid lowering drugs in IHD is secondary prevention, it is
clearly just as important that patients with angina receive
lipid lowering drugs as revascularised patients.
Lack of a regional pattern for statin treatment is in keeping
with other data on the lack of variation in treatment and con-
trol of hypertension22 and can be seen as a strength of a
universally available National Health Service. In an earlier
report based on the Health Survey for England8 we examined
Figure 3 Statin use among patients aged 35–84 years in whom IHD
is diagnosed by practice in 1998 (n = 142) and 2000 (n = 115).
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a broad range of socioeconomic factors and found no clear
association, though manual workers were slightly more likely
to be taking statins for secondary prevention of CHD. The
weak association with social status as assessed by the ACORN
score in the present study is consistent with the earlier report
and shows the advantage of a large sample size. Taken
together it seems unlikely that social factors have an
important role in determining who receives statins. The
slightly lower rate for smokers confirms an earlier report,8 is in
keeping with smokers being less likely to have their blood
pressure treated or controlled,22 and may be explained by
smokers being less likely to visit their general practitioner.
Our observations appear to elucidate the finding of
Hippisley-Cox and colleagues7 that women are less likely to
receive lipid lowering drugs than men. Our data may also
explain some of their other observed sex inequalities in IHD
secondary prevention. In our study women with IHD were
much less likely to have had revascularisation and were on
average considerably older. However, among patients who
were revascularised, women were more likely than men to be
taking a statin. It has been noted that women with IHD are
less likely to be investigated and to receive revascularisation23
but the reasons for this are not known. Our data confirm and
extend the observations of Reid and colleagues8 and suggest
that the reasons for the sex differences in IHD secondary pre-
vention measures may be more subtle than sex prejudice.24 25
Our study has the strength that all patients registered with
a practice were included. Thus, non-response bias is not an
issue and the large numbers of patients and practices provide
ample statistical power and generaliseability. The potential
weakness lies in selection of the practices. For example, it may
be that statin prescribing in DIN practices is higher because of
their interest in research. However, a recent paper26 provides
some reassurance that research practices do not differ much in
patient outcome and in this instance our main findings on
patient characteristics were robust to controlling for practice
and consistent with our recent analysis of Health Survey for
England data.8
Our observations show that clinical practice in the area of
lipid lowering has improved steadily over the past five years
but that there is room for further improvement in a number of
areas. In particular the low rates of prescribing among patients
with angina only and in those over age 65 appear illogical.
While the National Service Framework will probably lead to
improvements in prescribing for angina patients, the elderly
may continue to miss out on the benefits of statins unless
clearer guidance is given.
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